Avalo Therapeutics Inc (AVTX)

Currency in USD
13.950
-0.800(-5.42%)
Closed·
13.9200.000(0.00%)
·
AVTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.73015.110
52 wk Range
3.39020.720
Key Statistics
Prev. Close
14.75
Open
14.75
Day's Range
13.73-15.11
52 wk Range
3.39-20.72
Volume
712.13K
Average Volume (3m)
674.91K
1-Year Change
185.8607%
Book Value / Share
4.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.091
Upside
+187.39%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Avalo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Compare AVTX to Peers and Sector

Metrics to compare
AVTX
Peers
Sector
Relationship
P/E Ratio
−4.8x−3.1x−0.4x
PEG Ratio
−0.07−0.090.00
Price/Book
4.5x2.3x2.6x
Price / LTM Sales
6,316.4x45.1x3.2x
Upside (Analyst Target)
171.2%220.1%46.7%
Fair Value Upside
Unlock16.5%7.6%Unlock

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.091
(+187.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wolfe Research
Buy---New CoverageApr 08, 2026
Citizens
Buy52.00+272.76%-New CoverageApr 06, 2026
H.C. Wainwright
Buy40.00+186.74%25.00MaintainMar 25, 2026
BTIG
Buy40.00+186.74%-MaintainMar 23, 2026
Wedbush
Buy29.00+107.89%28.00MaintainMar 23, 2026

Earnings

Latest Release
Mar 23, 2026
EPS / Forecast
-0,75 / -1,25
Revenue / Forecast
59K / --
EPS Revisions
Last 90 days

AVTX Income Statement

FAQ

What Is the Avalo Therapeutics (AVTX) Stock Price Today?

The Avalo Therapeutics stock price today is 13,950 USD.

What Stock Exchange Does Avalo Therapeutics Trade On?

Avalo Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Avalo Therapeutics?

The stock symbol for Avalo Therapeutics is "AVTX."

What Is the Avalo Therapeutics Market Cap?

As of today, Avalo Therapeutics market cap is 370,390M USD.

What Is Avalo Therapeutics's Earnings Per Share (TTM)?

The Avalo Therapeutics EPS (TTM) is -5,840.

From a Technical Analysis Perspective, Is AVTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Avalo Therapeutics Stock Split?

Avalo Therapeutics has split 2 times.

How Many Employees Does Avalo Therapeutics Have?

Avalo Therapeutics has 33 employees.

What is the current trading status of Avalo Therapeutics (AVTX)?

As of Apr 24, 2026, Avalo Therapeutics (AVTX) is trading at a price of 13,950 USD, with a previous close of 14,750 USD. The stock has fluctuated within a day range of 13,730 USD to 15,110 USD, while its 52-week range spans from 3,390 USD to 20,720 USD.

What Is Avalo Therapeutics (AVTX) Price Target According to Analysts?

The average 12-month price target for Avalo Therapeutics is 40,091 USD, with a high estimate of 52 USD and a low estimate of 24 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +187,39% Upside potential.

What Is the AVTX Premarket Price?

AVTX's last pre-market stock price is 14,900 USD. The pre-market share volume is 18 450,000, and the stock has decreased by 0,150, or 1,020%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.